Last updated on July 2020

A Study to Assess AK002 in Eosinophilic Gastritis and/or Eosinophilic Duodenitis (Formerly Referred to as Eosinophilic Gastroenteritis)


Brief description of study

This is a Phase 3, multi-center, randomized, double-blind, placebo-controlled study to assess the efficacy and safety of antolimab (AK002), given monthly for 6 doses, in patients with moderately to severely active Eosinophilic Gastritis and/or Eosinophilic Duodenitis (formerly referred to as Eosinophilic Gastroenteritis) who have an inadequate response with, lost response to, or were intolerant to standard therapies

Clinical Study Identifier: NCT04322604

Find a site near you

Start Over

Allakos Investigational Site

Little Rock, AR United States
4.63miles
  Connect »

Recruitment Status: Open


Brief Description Eligibility Contact Research Team


Volunteer Sign-up

Sign up for our FREE service to receive email notifications when clinical trials are posted in the medical category of interest to you.